Athenex - ATNX Competitors

Athenex (NASDAQ:ATNX) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, community ranking, valuation, earnings, risk and dividends.

Do insiders & institutionals have more ownership in ATNX or ATNM?

40.9% of Athenex shares are held by institutional investors. Comparatively, 8.9% of Actinium Pharmaceuticals shares are held by institutional investors. 12.0% of Athenex shares are held by insiders. Comparatively, 1.3% of Actinium Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Which has stronger valuation and earnings, ATNX or ATNM?

Actinium Pharmaceuticals has lower revenue, but higher earnings than Athenex.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athenex	$120.18 million	0.54	-$199.77 million	-$1.72	-0.31
Actinium Pharmaceuticals	$1.14 million	125.60	-$24.77 million	N/A	N/A

Which has more volatility & risk, ATNX or ATNM?

Athenex has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Comparatively, Actinium Pharmaceuticals has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500.

Does the MarketBeat Community favor ATNX or ATNM?

Athenex received 293 more outperform votes than Actinium Pharmaceuticals when rated by MarketBeat users. Likewise, 65.84% of users gave Athenex an outperform vote while only 0.00% of users gave Actinium Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Athenex	Outperform Votes 293 65.84%	Underperform Votes 152 34.16%
Actinium Pharmaceuticals	Outperform Votes No Votes	Underperform Votes 2 100.00%

Do analysts prefer ATNX or ATNM?

Athenex currently has a consensus price target of $4.00, indicating a potential upside of 645.99%. Given Athenex's higher probable upside, analysts plainly believe Athenex is more favorable than Actinium Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athenex	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Is ATNX or ATNM more profitable?

Athenex has a net margin of -160.39% compared to Actinium Pharmaceuticals' net margin of -1,681.46%. Actinium Pharmaceuticals' return on equity of -32.44% beat Athenex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athenex	-160.39%	-258.81%	-43.21%
Actinium Pharmaceuticals	-1,681.46%	-32.44%	-30.36%

Does the media favor ATNX or ATNM?

In the previous week, Athenex had 14 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 15 mentions for Athenex and 1 mentions for Actinium Pharmaceuticals. Athenex's average media sentiment score of 0.67 beat Actinium Pharmaceuticals' score of 0.00 indicating that Athenex is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Athenex	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Actinium Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Athenex beats Actinium Pharmaceuticals on 11 of the 15 factors compared between the two stocks.